Compare FirstEnergy Corp. (FE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Inovio Pharmaceuticals Inc — how do they compare? FirstEnergy Corp. trades at $49.08 (market cap $28.13B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: FirstEnergy Corp. is far larger — about 292.2× Inovio Pharmaceuticals Inc's market cap, and FirstEnergy Corp. pays a 3.82% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FE | INO | |
|---|---|---|
Market Cap | $28.13B | $96.26M |
Sector | Utilities | Health |
52-Week High | $51.91 | $2.87 |
52-Week Low | $40.30 | $1.05 |
Enterprise Value | $56.14B | $67.27M |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $49.22, up 1.63% with a bullish technical signal. The stock shows consistent revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, supported by strong cash flow from operations of $3.70B. Recent news highlights growth from data center demand and a $36B investment plan.
Outlook remains positive due to strategic investments and rising energy demand, but risks include high debt levels and regulatory pressures. The stock offers steady growth potential with a dividend yield, though investors should monitor execution of capital expenditures and interest rate impacts on financing costs.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
